Can a Head-Down tilt or ancient herbs save lives in severe pneumonia?

NCT ID NCT07396701

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This large trial in China will test two additional treatments for people with severe pneumonia who need a breathing machine. One group will have their bed tilted head-down for at least 12 hours a day. Another group will receive a traditional Chinese herbal formula. The goal is to see if either approach lowers the chance of death within 28 days, compared to standard care alone. About 1,500 ICU patients will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Trendelenburg position (head-down tilt) and a traditional Chinese herbal formulation

What this could lead to

If successful, this could provide simple, low-cost additions to standard care that reduce deaths from severe pneumonia.

What could go wrong

This is an early-stage trial with no blinding, so results may be influenced by expectations. The herbal formula is complex and may cause side effects or interact with other drugs.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE PNEUMONIA WITH RESPIRATORY FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••